Unstandardized testings and lack of information mean that the public may have been misled as to the content of CBD products retailed in the UK. According to this article, the industry body has decided to take the lead and start setting standards for others in the market to follow.
Cannabidiol (CBD) is the second most prevalent of the active ingredients of cannabis. Other CBD manufacturers may claim that CBD oil is a cure-all for cancer, but it has never been proven so far though research shows that CBD can be an option for managing – not complete/total healing from – anxiety and/or depression, insomnia, acne, and chronic pain with proper diagnosis and dosage from a physician.
While there are different claims on whether that bottle of CBD oil can actually have good effects on your body, there’s a greater problem for this industry in the UK – that product may not contain any CBD at all, or worse, it may contain illegal amounts of tetrahydrocannabinol (THC) in it.
Cannabis oil is the most concentrated form, making it the most potent of the three main cannabis products, which are the actual cannabis flower or the marijuana, resin (hashish), and oil. Marijuana and hemp are like cousins when talking about plants; thus, people tend to interchange and confuse between the two.
On the other hand, CBD is from hemp, which is a breed of cannabis that is bred without THC – the chemical that is intoxicating and can get people “high.” CBD is considered a non-psychoactive component as it only contains less than 0.2% of the psychoactive THC, making it of legal use in the UK.
The bottom line is that cannabis oil may be dangerous for people’s health while CBD oil that contains high levels of cannabidiol and low THC is seen as medicinal as of the moment.
Based on a laboratory test from the Centre for Medicinal Cannabis (CMC) last June, nearly half of the products tested had low levels of THC. Though these products are unlikely to get anyone in critical conditions, they showed that the CBD industry’s standards are not at all high and are not properly regulated.
As seen from the recent press release statement given by the CMC, products can have varied results depending on who performs the testing as each laboratory utilizes separate testing methods. This can lead to companies obtaining reassuring results that do not honestly reflect what content the products have.
“It is a lack of domain experts in the field,” says Shomi Malik, the development director at CMC. The legality of CBD as for its medicinal use was only formalized in the UK last November, thus proving that they are short in numbers when it comes to experts that can perform quality lab test on certain CBD products.
“We at the CMC will be setting up the standard, that [says], ‘this is the quality we want in the testing of these samples’,” said Parveen Bhatarah, CMC’s compliance and regulatory lead. CMC stated that their goal is to either agree on standardisation methods or prove the equivalence in testing various product ranges such as products with cannabinoid contents.
Bhatarah ends the press statement saying that the need for standardisation is damaging the industry and their initiative to create one is significant for it to continue to grow.